The simian immunodeficiency virus (SIV)-newborn rhesus macaque model of AIDS can be used to study directly the virulence of viral mutants which are resistant to antiviral drugs. A viral mutant called SIVmac79A6.1, isolated from an SIV-infected macaque after prolonged zidovudine treatment, was found to have a double-base-pair change at codon 151 of reverse transcriptase, resulting in a glutamine to methionine substitution (Q151M). This mutation was associated with more than 100-fold increased resistance to zidovudine and low-level cross-resistance to other dideoxynucleoside analogs. To determine whether this Q151M mutation affects viral virulence, four newborn macaques were inoculated intravenously with a biological clone of this drug-resistant SIVmac79A6.1 mutant; two of these animals were also treated orally with zidovudine. All four animals showed persistent viremia, and two of the four animals developed fatal immunodeficiency at 3 and 8 months of age, respectively. The remaining two animals had CD4 ؉ T-cell depletion and clinical symptoms of AIDS at 22 months. No phenotypic or genotypic reversion of virus to the wild type could be detected in any of the four animals. These results demonstrate that the Q151M mutation in SIV reverse transcriptase does not reduce viral virulence.
An important and yet largely unanswered question regarding anti-human immunodeficiency virus (HIV) drug therapy concerns the clinical implications of drug-resistant HIV mutants: Are drug-resistant mutants fully virulent, and does their emergence contribute to reduced efficacy or failure of drug therapy? For nonnucleoside reverse transcriptase (RT) inhibitors such as nevirapine and L-697,661, the rapid development of resistance within 1 month has been associated with a loss of antiviral drug activity, and the clinical significance of resistance has been established (5, 27, 30, 31, 51) . However, the clinical significance of in vitro drug resistance has been difficult to elucidate for the nucleoside analogs such as 3Ј-azido-3Ј-deoxythymidine (AZT; zidovudine), 2Ј,3Ј-dideoxyinosine (ddI; didanosine), or 2Ј,3Ј-dideoxycytidine (ddC; zalcitabine), where suppression of viral replication is more prolonged and the emergence of drug-resistant mutants is much slower. Although the emergence of these viral mutants is often associated with a decline in the health of HIV-infected adults and infants (6, 12, 20, 22, 23, 42) , this correlation is not necessarily causative (for reviews, see references 8, 26-28, and 50) .
Attempts to demonstrate the virulence of drug-resistant HIV mutants by conducting studies with human patients are extremely difficult or even impossible (for a review, see reference 26). Although primary infection with AZT-resistant HIV has been observed and can be indicative of the replicative potential of these mutants (7, 9, 10, 14, 19, 39, 40) , it would be more desirable to have an idea about the pathogenic potential of drug-resistant viral mutants prior to the large-scale clinical application of novel compounds.
An appropriate animal model can help to gain insight into the clinical implications of drug-resistant viral mutants. We have previously shown that newborn macaques inoculated with simian immunodeficiency virus (SIVmac) are a practical animal model of AIDS and allow for the rapid and reliable evaluation of the virulence of viral variants and of the efficacy of antiviral drug therapy (18, 46, 47, 49) ; the information obtained with this pediatric animal model of AIDS should also apply to the adult population (1) . Accordingly, this animal model of AIDS provides a system that can be used to study (i) if drug resistance mutations affect viral virulence and (ii) if drug resistance can be responsible for the loss or a reduction of the efficacy of drug treatment.
We previously isolated an AZT-resistant SIVmac mutant from an SIV-infected macaque after prolonged AZT therapy (47) . In the present study, we demonstrate that this AZTresistant SIVmac mutant, which had a glutamine-to-methionine substitution at amino acid 151 of RT (Q151M), was able to cause fatal immunodeficiency following inoculation into newborn macaques.
MATERIALS AND METHODS
Biological cloning of AZT-resistant SIVmac. An AZT-resistant virus isolate, obtained from an SIV-infected infant macaque after prolonged AZT treatment (as described previously [47] ), was serially diluted and cultured with CEMϫ174 cells in 96-well plates (at eight replicates per dilution) in the presence of 60 M AZT. After 5 days, cell-free supernatants from individual wells containing the highest dilution that had detectable p27 by an antigen-capture enzyme-linked immunosorbent assay (ELISA) (16) were briefly propagated on CEMϫ174 cells and were serially diluted to infect the next round of CEMϫ174 cells. After three rounds of limiting dilution culture, the biological clone SIVmac79A6.1 with highly reduced susceptibility to AZT was isolated.
Animal procedures. Four newborn rhesus macaques (Macaca mulatta) from type D retrovirus-and SIV-seronegative dams at the California Regional Pri-mate Research Center were removed from their mothers and hand-reared in a primate nursery in accordance with American Association for Accreditation of Laboratory Animal Care Standards. When necessary, animals were immobilized with ketamine HCl (Parke-Davis, Morris Plains, N.J.) at 10 mg/kg of body weight injected intramuscularly.
The four newborn rhesus monkeys were divided into two groups. Between 1 and 2 days after birth, all four animals were inoculated intravenously with 1 ml of a 10 Ϫ1 dilution in phosphate-buffered saline (equivalent to 100 to 500 50% tissue culture infectious doses [TCID 50 s]) of tissue culture supernatant of the biological clone SIVmac79A6.1 propagated in CEMϫ174 cells. Two of these four animals were also treated orally with AZT (25 mg/kg every 8 h) (47) . AZT treatment was started at the time of virus inoculation, and administration of AZT syrup (10 mg/ml; Retrovir) was performed as described previously (47) .
Blood samples were collected regularly for monitoring toxicity and viralimmunologic parameters as described previously (45, 47) . Complete blood counts were performed with EDTA-anticoagulated blood samples from all animals. Samples were analyzed by using an automated electronic cell counter (Baker 9000; Serono Baker Diagnostics); differential cell counts were determined manually.
Drug susceptibility assay. The phenotypic drug susceptibilities of the SIVmac strains were characterized by a previously described assay, based on a dosedependent reduction of viral infectivity (47) . In brief, titration of tissue culture supernatants for viral infectivity (by making fivefold dilutions with eight replicates per dilution and adding CEMϫ174 cells in 96-well plates, followed after 5 days by p27 antigen measurement [16] ) was performed at various drug concentrations, and infectious titers (TCID 50 s per milliliter) were calculated. The inhibitory concentration which reduced infectivity by 50% (IC 50 ) or 90% (IC 90 ) was determined (47) .
DNA preparation, PCR, and cloning. Peripheral blood mononuclear cells (PBMCs) were collected at regular time points from all four animals. In addition, lymph node, spleen, and thymus were collected at the time of necropsy. DNA was extracted with the QIAmp Blood Kit (Qiagen, Inc., Chatsworth, Calif.) and was used to amplify a 1,500-bp region encompassing the Q151M mutation in the RT gene by PCR on a GeneAmp 9600 thermal cycler (Perkin-Elmer Cetus, Emeryville, Calif.). After an initial denaturing step (30 s at 96ЊC), nested PCR was conducted under the following conditions: 29 cycles of 30 s at 95ЊC, 30 s at 60ЊC, and 1.5 min at 72ЊC, followed by a final cycle of 30 s at 95ЊC, 30 s at 60ЊC, and 5 min at 72ЊC. The sequences of the primer pairs which were used for nested PCR were as follows: primer RT-1, 5Ј-GGATTAAAGGGACAATCATGACA GGG-3Ј; (nucleotides [nt] 3018 to 3043); RT-12, 5Ј-CACAGGTGTCTACTAT CTGTCTGGCCAC-3Ј (nt 4905 to 4878) (RT-1 and RT-12 were the external primer set); RT-11, 5Ј-GGCTCGAATTCAGCTCTGGGGATGTCTC-3Ј (nt 3077 to 3099 with GGCTC on the 5Ј end); and RT-14, 5Ј-GGCCCTAAGCTT GTCAATGCCATGAG-3Ј (nt 4576 to 4551 with a GGCCC on 5Ј end). RT-11 and RT-14 were the internal primers and were designed to contain EcoRI and HindIII restriction sites (underlined sequences), respectively.
PCR products were purified with the QIAquick PCR purification kit (Qiagen, Inc.). Purified DNA fragments from the latest time point for each animal were cloned into the pGem-3Z vector (Promega, Madison, Wis.) and were grown in competent Escherichia coli DH␣5 cells (Gibco BRL, Rockville, Md.) according to the manufacturer's instructions. Plasmid DNA was purified with the QIAwell 8 Plus Plasmid Kit (Qiagen, Inc.).
DNA sequencing and analysis. To check for the presence of the Q151M mutation, approximately 300 bp surrounding the mutation was sequenced directly from purified PCR fragments from each time point on a model 373A automated sequencer by the Dye-Deoxy terminator method (Applied Biosystems, Inc., Foster City, Calif.). In addition, at least five plasmid clones from the latest time points for all four animals were sequenced to verify the Q151M mutation. The sequence of the entire RT was also determined directly from purified PCR fragments obtained at the latest time point. The sequences of all forward and reverse primers used for sequencing are available upon request. Sequencing analyses were performed with Sequence Navigator and Auto Assembler computer programs (Applied Biosystems, Inc.).
Quantitative virus isolation (cell-associated and cell-free virus). Cell-associated and cell-free virus levels in peripheral blood were determined regularly by limiting dilution culture assays (four replicates per dilution) of PBMCs or plasma in CEMϫ174 cells in 24-well plates; virus replication was monitored by a p27 core antigen capture assay (45, 47) . Virus levels in fresh spleen, thymus, and peripheral lymph node were determined by a limiting dilution culture assay of single-cell suspensions by a method similar to that used for PBMCs.
Anti-SIV isotype-specific antibody determination. The isotype-specific antibody ELISAs have been described previously (24) . Briefly, for the SIV-specific immunoglobulin G (IgG) and IgA antibody ELISA, uncloned SIVmac was concentrated by centrifugation, disrupted in 1% sodium dodecyl sulfate, and applied to microtiter ELISA plates (Falcon 3912; Becton Dickinson, San Jose, Calif.) at 100 ng of total protein per well. The plates were then incubated with test or control plasma samples (1:100), washed, incubated with 1:1,000-diluted enzymeconjugated goat anti-monkey IgG or IgA (Nordic, Capistrano Beach, Calif.), washed again, incubated with o-phenylenediamine (Sigma Chemical Co.) as substrate, and read spectrophotometrically. The SIV-specific IgM antibody ELISA was performed on plates coated with a 21-amino-acid synthetic peptide derived from the SIVmac transmembrane glycoprotein and is described elsewhere (24) . Immunoblotting was performed as described previously (41) .
T-lymphocyte phenotyping. T-lymphocyte antigens were detected by direct labeling of whole blood with fluorescein-conjugated anti-human CD8 (Leu-2a; Becton Dickinson Immunocytometry Inc., San Jose, Calif.) and phycoerythrinconjugated anti-human CD4 (OKT4; Ortho Diagnostic Systems Inc., Raritan, N.J.). Erythrocytes were lysed, and the samples were fixed in paraformaldehyde by using the Coulter Q-prep system (Coulter Corporation, Hialeah, Fla.). Lymphocytes were gated by forward and side light scatter and were then analyzed with a FACSCAN flow cytometer (Becton Dickinson).
Collection of tissue samples at necropsy and preparation of tissue samples. Animals were euthanized when it became apparent that their condition was terminal (48) . A complete necropsy examination was performed for all animals that died during the course of the study. Tissues collected at necropsy were fixed in 10% buffered formalin, embedded in paraffin, sectioned at 6 m, stained with hematoxylin-eosin, and examined by light microscopy.
Nucleotide sequence accession number. The RT sequence of the SIVmac 79A6.1 inoculum is available through GenBank (accession number U65787).
RESULTS
In vivo selection for AZT-resistant SIVmac. An AZT-resistant SIVmac strain was isolated from an 8-month-old infant macaque that had been inoculated at birth with drug-sensitive, uncloned SIVmac251 and was started on chronic AZT treatment immediately afterward (47) . The emergence of drug resistance in the virus infecting this animal was temporally associated with an increase in viremia, the development of thrombocytopenia (platelet counts, Ͻ1.5 ϫ 10 5 /l), persistent lymphopenia (Ͻ1,500 lymphocytes/l), and progressive CD4 ϩ T-cell depletion (CD4 ϩ T-cell counts were consistently Ͻ200/l starting at 8 months and Ͻ110/l from 10 months on). This animal finally succumbed to fatal immunodeficiency 16 months after virus inoculation, despite continuing AZT treatment. Histopathological examination demonstrated severe lymphoid depletion and the presence of opportunistic infections (data not shown).
In vitro characterization of AZT-resistant SIVmac: Q151M mutation associated with multiple drug resistance. The AZTresistant SIVmac isolate obtained from the AZT-treated SIVinfected animal (see above) was biologically cloned by three sequential limiting dilutions. The AZT-resistant phenotype of one clone, designated by the name SIVmac79A6.1, was confirmed (Ͼ100-fold increased IC 90 ; Table 1 ). The RT region of SIVmac79A6.1 was characterized by DNA sequence analysis by standard procedures. Compared to the uncloned SIVmac 251 inoculum and an early therapy isolate from this animal, the only mutations in RT were a double-base-pair change at RT codon position 151 (CAG to ATG), resulting in an amino acid change of glutamine to methionine (Q151M; GenBank accession number U65787); this Q151M mutation has not been reported previously for any SIV isolate (21). SIVmac79A6.1 was found to have significant resistance to ddI (10-fold) but minor resistance to ddC (5-fold), stavudine (d4T; 3-fold), and Table 1) . Inoculation of SIVmac79A6.1 in newborn macaques results in fatal disease. Four newborn rhesus macaques (Ͻ3 days of age) were inoculated intravenously with 100 to 500 TCID 50 s of the AZT-resistant biological clone SIVmac79A61 ( Table 2) . Two of these four animals were also started on oral AZT treatment (25 mg/kg three times per day orally) at the time of virus inoculation; this AZT dosage regimen was previously shown to have strong therapeutic effects against AZT-sensitive SIVmac (47) .
All four animals, including the two AZT-treated animals, developed high levels of PBMC-associated and plasma viremia during the first weeks after inoculation (Fig. 1) . The viremia in the two AZT-treated animals was lower than that in the two untreated SIVmac79A6.1-inoculated infants. The magnitude of the initial viremia of AZT-resistant SIVmac79A6.1 in newborn macaques was similar to that previously observed in newborn macaques infected with uncloned AZT-sensitive SIVmac251 in the absence of AZT treatment, and the viremia occurred 1 week earlier than that seen for AZT-sensitive virus in the presence of AZT treatment (47) (Fig. 1) .
For animal 28008, which was not treated with AZT, PBMCassociated and plasma virus levels remained persistently high (Fig. 1) . This animal made SIV-specific IgM (data not shown) but did not mount detectable SIV-specific IgG or IgA responses, as determined by ELISA and immunoblotting (data not shown). Animal 28008 was euthanized at 12 weeks with very widespread SIV dissemination (Table 3) , and clinical symptoms and pathologic lesions diagnostic of simian AIDS (poor weight gain, hypoproteinemia [plasma protein concentration, 4.1 g/dl], interstitial pneumonia, lymphadenitis, cholangiocystitis, and cytomegalovirus and cryptosporidium infections). The other three animals which were inoculated with SIVmac79A6.1 were able to make anti-SIV IgG and IgA (Table 2; data not shown) and showed a decrease in plasma viremia (Fig. 1) . Of these three animals, animal 28005, which had received continuous AZT treatment since birth, developed thrombocytopenia (platelet counts, Ͻ0.5 ϫ 10 5 /l) and hypoproteinemia (plasma protein concentration, 4.2 g/dl) and was euthanized at 32 weeks of age. Histopathologic examination of animal 28005 demonstrated lymphadenitis, glomerulo- a All four macaques were inoculated intravenously within 3 days of birth with 1 ml (100 to 500 TCID 50 s) of the AZT-resistant biological clone SIVmac79A6.1.
b Animals 27999 and 28005 were given oral AZT treatment of 25 mg/kg three times per day, starting at the time of virus inoculation.
c Anti-SIV IgG antibody (Ab) response detected by whole-virus ELISA and immunoblotting.
FIG. 1. Viremia levels during the first 15 weeks of SIV infection. PBMCassociated and plasma virus levels were determined by a limiting dilution culture with CEMϫ174 cells. At time zero, four newborn macaques were inoculated intravenously with AZT-resistant SIVmac79A6.1, and two of them were started on chronic AZT treatment. Euthanasia of animal 28008 due to simian AIDS at 12 weeks of age is indicated (ϩ). For comparison, the two shaded areas represent the range of virus levels for animals previously inoculated with the AZT-sensitive parental virus, uncloned SIVmac251; a subgroup of these animals was started on AZT at day 0; most untreated SIVmac251-inoculated infants died within 12 weeks of age; more details about the SIVmac251-infected animals are found elsewhere (47) . a Following inoculation at birth with SIVmac79A6.1, animals 28008 and 28005 developed simian AIDS and were euthanized at 12 and 32 weeks, respectively. Cell-associated and cell-free virus levels in peripheral blood and fresh lymphoid tissues collected at the time of necropsy were determined by limiting dilution culture of single-cell suspensions or plasma and are expressed as the numbers of TCID 50 s per 10 6 cells or per milliliter of plasma.
nephritis, lung arteriopathy, and megakaryocytic hyperplasia of the bone marrow. The two remaining animals (animals 27999 and 28006) had persistent PBMC-associated viremia and showed inversed CD4 ϩ / CD8 ϩ T-lymphocyte ratios from approximately 6 months of age on (Table 4 ). Animal 28006 also had a progressive and severe reduction in absolute numbers of CD4 ϩ T-lymphocytes and persistent thrombocytopenia ( Table 4) . Both of these animals had chronic diarrhea (they were positive for cryptosporidium) and poor weight gain at 95 weeks of age.
Virus isolated from the PBMCs and plasma of the four animals at the latest available time point (i.e., either at the time of death or at 95 weeks of age) was also tested for drug susceptibility, and all virus isolates remained highly AZT resistant (data not shown). Sequence analysis of plasmid clones with proviral DNA from all four animals at 3 weeks after virus inoculation and at the latest available time point also demonstrated the Q151M mutation ( Table 5 ). The entire RT region of the proviral DNA from the latest time point available (i.e., at the time of death or at 95 weeks of age) was also sequenced to detect additional mutations. In comparison with the virus inoculum SIVmac79A6.1, no other mutations were found in the RT region except for a V17D and a D44E mutation for animal 28006 and a S338A mutation for animal 27999. All these mutations, except the Q151M mutation, have been described previously for other SIV or HIV isolates (21) and have not been associated with antiviral drug resistance.
DISCUSSION
An AZT-resistant mutant virus called SIVmac79A6.1 was previously isolated from an SIV-infected infant macaque after prolonged AZT therapy and showed high-level resistance to AZT. No mutations were found at the five sites which are most commonly responsible for AZT resistance in HIV-infected people on AZT monotherapy, namely, amino acid positions 41, 67, 70, 215, and 219 (13, 15) . Instead, a Q151M mutation was detected in AZT-resistant SIVmac79A6.1. The Q151M mutation is being found at increasing frequency in HIV type 1 (HIV-1) isolates from patients receiving prolonged combination therapies of AZT plus ddI or AZT plus ddC, but it has also been found during sequential therapy with these dideoxynucleosides (11, 17, 32, 33, (35) (36) (37) (38) 43) . The Q151M mutation in HIV-1 isolates is associated with the development of high-level drug resistance to AZT and moderate to low-level resistance to ddI, ddC, 3TC, and d4T (11, 17, 32, 33, (35) (36) (37) (38) 43) . Accordingly, we found that SIVmac79A6.1 had a similar pattern of cross-resistance to these drugs. Amino acid 151 belongs to a highly conserved motif, thought to be part of the active site of the HIV-1 RT (4).
In HIV-1-infected individuals receiving prolonged dideoxynucleoside analog combination therapy, the development of this Q151M mutation has been associated with a sudden increase in viremia and precedes the development of four additional mutations: A62V, V75I, F77L, and F116Y (11, 17, 33, (35) (36) (37) (38) 43) . In addition to these five mutations, many other mutations in HIV-1 RT have been found in individual subjects, including V118I, D123E, I135V, I202V, and K219E (11, 33, 37, 38) . Interestingly, several of the mutant amino acids found in the multiple-drug-resistant HIV-1 isolates, namely, I-75, I-118, E-123, V-135, V-202, and E-219, are already present in wildtype SIVmac and were also conserved in our SIVmac79A6.1 mutant. Although it is unclear why a Q151M RT mutant of SIVmac was isolated after AZT monotherapy instead of combination therapy, it is possible that the conformational structure of the SIV RT predisposed SIV to the development of the Q151M mutation in RT rather than the mutations more commonly associated with HIV-1 resistance to AZT. In this context, Iversen et al. (11) reported that an HIV-1 clone with F77L and Q151M substitutions replicated very poorly in vitro unless they were accompanied by a V75I substitution; thus, the presence of isoleucine at position 75 in wild-type SIVmac may predispose SIVmac to the development of a Q151M mutation under AZT selection pressure. In support of this observation, a second AZT-treated SIV-infected rhesus macaque from our previous study (47) also developed the Q151M mutation and died as a result of simian AIDS (data not shown).
The Q151M mutation has not been reported previously for any SIV or HIV isolate in the absence of drug treatment; therefore, it might be assumed that this mutation may affect a All four animals were inoculated at birth with SIVmac79A6.1, which has a Q151M mutation in RT. A region encompassing the Q151M mutation (at least 300 bp) was sequenced from PBMC and lymphoid tissue DNA. M, mutant codon ATG (methione); the wild-type codon is CAG (glutamine). For the latest available time point for each animal, at least five plasmid clones were analyzed; all clones were found to have M at codon 151. Animals 28008 and 28005 developed simian AIDS and were euthanized at 12 and 32 weeks of age, respectively. the replicative potential of the virus. However, inoculation of newborn macaques with the Q151M RT mutant SIVmac 79A6.1 demonstrated that this mutation caused minimal impairment of the replicative potential of SIVmac. Following inoculation into newborn macaques, SIVmac79A6.1 replicated efficiently during the initial weeks of infection, even in the presence of AZT therapy, caused persistent viremia, and was able to induce immunodeficiency (simian AIDS). There was no evidence of genotypic or phenotypic reversion of codon 151 in the four animals in this study. The stability of the mutation can partially be explained by the requirement of a simultaneous 2-bp change (ATG to CAG). However, reversion was not even seen in untreated animal 28006 after 95 weeks of virus replication; for this animal, there was no selection pressure by AZT treatment to retain an AZT resistance phenotype; thus, this finding suggests that the driving forces of replicative fitness did not exert sufficient selection pressure to result in detectable reversion to wild-type virus in this animal. Slow reversion rates have also been observed in people infected with AZT-resistant HIV-1 in the absence of AZT treatment (2, 3, 25, 52) .
The very rapid and fulminant disease course of SIV infection in animal 28008 indicates that the AZT resistance genotype and phenotype are compatible with high virulence: this animal showed a disease course characterized by persistently high viremia levels and no anti-SIV IgG or IgA responses, similar to that generally observed after intravenous or oral inoculation of newborns macaques with highly virulent uncloned SIVmac251 (18, 24, 47, 48, 49) . The other three animals in this study were able to mount an SIV-specific antibody response, and their time course to the development of fatal disease resembled that observed following inoculation of newborn macaques with the pathogenic molecular clone SIVmac239 (18) .
The demonstration that the Q151M mutation does not reduce viral virulence suggests that the emergence of this mutant during AZT therapy of SIV-infected macaques contributes to disease progression and reduced efficacy of drug therapy. There was some indication that the Q151M mutation did not completely abolish the therapeutic effects of AZT therapy. Although the numbers of animal in this study were small, a comparison of the initial levels of viremia for AZT-resistant SIVmac79A6.1 with those previously obtained with wild-type, AZT-sensitive SIVmac251 (from which SIVmac79A6.1 was derived) suggests that AZT therapy was still somewhat beneficial for SIVmac79A61-inoculated newborns, even though SIVmac79A6.1 was highly resistant to AZT in vitro (Fig. 1) . Because newborn macaques have impaired AZT clearance, resulting in higher and more prolonged blood AZT levels (47), our results support the hypothesis by Richman (27, 29) that some clinical efficacy may still be obtained in the presence of drug-resistant virus if high levels of the drug are achieved in plasma.
In conclusion, the experiment described here demonstrates the usefulness of the SIV-macaque model for studying the virulence of drug-resistant mutants. We demonstrated that a Q151M mutation in the RT region does not reduce the virulence of SIVmac. The observation of an increasing prevalence of the Q151M mutation in HIV-1 isolates from human subjects on prolonged combination therapy with dideoxynucleoside analog RT inhibitors (17, 33, 36) and the compatibility of the Q151M mutation with mutations conferring resistance to additional RT inhibitors (32, 34, 44) should raise concerns.
